ArticleCA: a cancer journal for clinicians2018
Ovarian cancer statistics, 2018.
Article in CA: a cancer journal for clinicians, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 2,080 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label, Phase II Clinical Trial of of a Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Adverse Reactions Nausea of Niraparib in in the First-line Maintenance Treatment in Advanced Epithelial Ovarian Cancer (EOC) Patients
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
Clinical and Pathological Characteristics of Women With Ovarian Cancers, A National, Retrospective Cross-Sectional Study in Syria During the War
Who cites it
2,080 citing papers in PubMed, 5 syntheses or guidelines pooled it, 3,678 citations in OpenAlex.
- Survival Patterns of Patients with Ovarian Cancer in Africa: Systematic Review and Meta-analysis.Annals of surgical oncology · 2026Pooled it
- The Impact of Chronic Stress on Treatment Outcomes of Cancer Patients with Divergent Survival Rates: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Comparative efficacy and safety of different treatment strategies for primary advanced ovarian cancer: a systematic review and network meta-analysis of randomized control trials.Frontiers in oncology · 2026Pooled it
- The effects of vitamin D levels on risk and prognosis of ovarian cancer: a systematic review.Cancer causes & control : CCC · 2025Pooled it
- Causal inference in the diagnosis and prognosis of ovarian cancer: current state and future directions.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- FOXM1 drives cisplatin resistance in ovarian cancer through STIM1-mediated SOCE and STAT1 activation.Molecular therapy. Oncology · 2026Article
- A photothermal ablation strategy for orthotopic ovarian cancerInternational journal of pharmaceutics: X · 2026Article
- Brain metastases as a manifestation of late relapse in high-grade serous ovarian cancer: Diagnostic and therapeutic challenges.Radiology case reports · 2026Article
- Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective study.International journal of clinical oncology · 2026Article
- Cold atmospheric plasma treated medium (PTM) induce antitumor effects in human ovarian cancer cells.Cancer cell international · 2026Article
- Bridging the gap between guidelines and practice: genetic counseling uptake and barriers in patients with ovarian malignancies.BMC women's health · 2026Article
- Global, regional, and national burden of ovarian cancer from 1990 to 2021: Analysis of risk factors and prediction of trends in 2050.Medicine · 2026Article
- Review
- Evaluation of Phytocannabinoids as Antitumor Agents against Ovarian Cancer Cells in Combination with Carboplatin.ACS omega · 2026Article
- Mechanistic Insights intoInternational journal of molecular sciences · 2026Article
- PiggyBac-Engineered Membrane-Bound IL7 TILs Combined with Anti-PD-1 Antibody Demonstrates Efficacy in Recurrent Ovarian Cancer: A First-in-Human Phase I Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- BRCA1/2-stratified immune profiling of treatment-naive high-grade serous ovarian cancer ascites identifies a Treg-enriched ascitic immune phenotype.Journal of pathology and translational medicine · 2026Article
- GPR107-EGFR crosstalk promotes ovarian cancer metastasis by regulating IL-6 release via PI3K/AKT/NF-κB signaling pathway.Translational oncology · 2026Article
- The KPROCS Study: A Real-World and Research Resource to Investigate Multilevel Determinants of Ovarian Cancer Treatment and Survival.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- High-grade serous ovarian cancer is associated with increased TP53 mutation burden in uterine lavage.NPJ precision oncology · 2026Article
2,020 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States. Herein, the American Cancer Society provides an overview of ovarian cancer occurrence based on incidence data from nationwide population-based cancer registries and mortality data from the National Center for Health Statistics. The status of early detection strategies is also reviewed. In the United States, the overall ovarian cancer incidence rate declined from 1985 (16.6 per 100,000) to 2014 (11.8 per 100,000) by 29% and the mortality rate declined between 1976 (10.0 per 100,000) and 2015 (6.7 per 100,000) by 33%. Ovarian cancer encompasses a heterogenous group of malignancies that vary in etiology, molecular biology, and numerous other characteristics. Ninety percent of ovarian cancers are epithelial, the most common being serous carcinoma, for which incidence is highest in non-Hispanic whites (NHWs) (5.2 per 100,000) and lowest in non-Hispanic blacks (NHBs) and Asians/Pacific Islanders (APIs) (3.4 per 100,000). Notably, however, APIs have the highest incidence of endometrioid and clear cell carcinomas, which occur at younger ages and help explain comparable epithelial cancer incidence for APIs and NHWs younger than 55 years. Most serous carcinomas are diagnosed at stage III (51%) or IV (29%), for which the 5-year cause-specific survival for patients diagnosed during 2007 through 2013 was 42% and 26%, respectively. For all stages of epithelial cancer combined, 5-year survival is highest in APIs (57%) and lowest in NHBs (35%), who have the lowest survival for almost every stage of diagnosis across cancer subtypes. Moreover, survival has plateaued in NHBs for decades despite increasing in NHWs, from 40% for cases diagnosed during 1992 through 1994 to 47% during 2007 through 2013. Progress in reducing ovarian cancer incidence and mortality can be accelerated by reducing racial disparities and furthering knowledge of etiology and tumorigenesis to facilitate strategies for prevention and early detection. CA Cancer J Clin 2018;68:284-296. © 2018 American Cancer Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.